Horisawa Yoshihito, Matsumoto Tadahiko, Takeda June, Tashiro Yusuke, Nomura Ryosuke, Takeuchi Suguru, Kawai Yugo, Kazuma Yasuhiro, Konishi Yoshinobu, Yamazaki Hiroyuki, Matsui Hiroyuki, Shirakawa Kotaro, Takaori-Kondo Akifumi
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Cancer Rep (Hoboken). 2025 Apr;8(4):e70189. doi: 10.1002/cnr2.70189.
DNA cytosine deaminase APOBEC3B (A3B) is one of the endogenous sources of somatic mutations in many types of human cancers and is associated with tumor progression rather than tumorigenesis. However, it remains uncertain whether APOBEC3B-induced mutations accelerate tumor progression or not. In this paper, we established a mouse model with A3B overexpression and investigated whether the introduction of A3B overexpression accelerates tumor development in Tp53 hemizygous mice.
We established A3B transgenic mouse by microinjection and selected the mouse which has only one A3B transgene by genomic qPCR and southern blotting using the probe against the transgene. A3B expression was validated by qPCR, immunoblotting, immunohistochemistry and in vitro CDA assays using lysates of this transgenic mouse liver, spleen and bone marrow. We interbreed this transgenic mouse model with CAG-Cre and Tp53 knockout mice and observed differences in tumor progression and survival between Tp53 hemizygous mice and Tp53 homozygous mice irrespective of A3B expression. Finally, comprehensive genomic mutation analysis was done using the developed tumors.
We established A3B transgenic mouse which has only one transgene. A3B expression and its CDA activity were confirmed in liver cells and tumor tissues of mice overexpressing A3B. Tp53 hemizygous mice developed osteosarcomas, spindle and pleomorphic sarcomas, and squamous cell carcinomas, however we did not observe any difference in tumor development between the mice with or without A3B expression. The tumor with A3B expression has more high-VAF mutations than the one without A3B, but these mutations are not APOBEC signature.
We developed a Cre inducible A3B transgenic mouse model bearing single copy of A3B gene. Although the introduction of A3B overexpression did not accelerate tumor development in Tp53 hemizygous mice, our mouse model with A3B overexpression is well-validated and useful for further research.
DNA胞嘧啶脱氨酶载脂蛋白B mRNA编辑酶催化多肽样3B(APOBEC3B,A3B)是多种人类癌症中体细胞突变的内源性来源之一,且与肿瘤进展而非肿瘤发生相关。然而,APOBEC3B诱导的突变是否加速肿瘤进展仍不确定。在本文中,我们建立了A3B过表达的小鼠模型,并研究了A3B过表达的引入是否会加速p53半合子小鼠的肿瘤发展。
我们通过显微注射建立了A3B转基因小鼠,并使用针对转基因的探针通过基因组定量聚合酶链反应(qPCR)和Southern印迹法筛选出仅具有一个A3B转基因的小鼠。通过qPCR、免疫印迹、免疫组织化学以及使用该转基因小鼠肝脏、脾脏和骨髓裂解物的体外胞嘧啶脱氨酶(CDA)测定来验证A3B的表达。我们将该转基因小鼠模型与CAG-Cre和p53基因敲除小鼠杂交,并观察p53半合子小鼠和p53纯合子小鼠之间肿瘤进展和生存的差异,而不考虑A3B的表达情况。最后,对所形成的肿瘤进行全面的基因组突变分析。
我们建立了仅具有一个转基因的A3B转基因小鼠。在过表达A3B的小鼠的肝细胞和肿瘤组织中证实了A3B的表达及其CDA活性。p53半合子小鼠发生了骨肉瘤、梭形和多形性肉瘤以及鳞状细胞癌,然而,我们未观察到有或没有A3B表达的小鼠之间在肿瘤发展上有任何差异。有A3B表达的肿瘤比没有A3B表达的肿瘤具有更多的高变异等位基因频率(VAF)突变,但这些突变并非APOBEC特征性突变。
我们开发了一种携带单拷贝A3B基因的Cre诱导型A3B转基因小鼠模型。尽管A3B过表达的引入并未加速p53半合子小鼠的肿瘤发展,但我们的A3B过表达小鼠模型经过了充分验证,可用于进一步研究。